<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One hundred consecutive patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) received horse antilymphocyte globulin (ALG), <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (CyA), <z:chebi fb="0" ids="50366">6-methylprednisolone</z:chebi> (6Mpred), and granulocyte colony-stimulating factor (G-CSF) as first-line therapy </plain></SENT>
<SENT sid="1" pm="."><plain>The median age was 16 years (range, 1-72 years) and median neutrophil count was 0.2 x 10(9)/L (range, 0-0.5 x 10(9)/L) </plain></SENT>
<SENT sid="2" pm="."><plain>Trilineage hematologic recovery (at a median interval of 96 days from treatment) was seen in 77 patients (48 complete, 29 partial) after 1 (n = 50) or more courses of ALG (n = 27) </plain></SENT>
<SENT sid="3" pm="."><plain>Of the 23 nonresponders, 11 patients died at a median interval of 83 days (range, 16-1132 days), 6 were considered treatment failures and underwent transplantation, and 6 were pancytopenic </plain></SENT>
<SENT sid="4" pm="."><plain>Cytogenetic abnormalities were seen in 11% of patients, clonal <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic disease</z:e> in 8%, and relapse of marrow <z:mpath ids='MPATH_58'>aplasia</z:mpath> in 9% </plain></SENT>
<SENT sid="5" pm="."><plain>The actuarial survival at 5 years was 87% (median follow-up 1424 days): 76% versus 98% for patients with neutrophil counts less than versus greater than 0.2 x 10(9)/L (P =.001) and 88% versus 87% for patients aged less than versus more than 16 years (P =.8) </plain></SENT>
<SENT sid="6" pm="."><plain>The actuarial probability of discontinuing CyA was 38% </plain></SENT>
<SENT sid="7" pm="."><plain>Patients who did not achieve a white blood cell (WBC) count of 5 x 10(9)/L during G-CSF treatment have a low probability of responding (37%) and a high mortality rate (42%) </plain></SENT>
<SENT sid="8" pm="."><plain>This update confirms a high probability for SAA patients of becoming transfusion independent and of surviving after treatment with ALG, CyA, 6Mpred, and G-CSF, with a significant effect of neutrophil counts on outcome </plain></SENT>
<SENT sid="9" pm="."><plain>Problems still remain, such as absent or incomplete responses, <z:e sem="disease" ids="C1516669" disease_type="Neoplastic Process" abbrv="">clonal evolution</z:e>, relapse of the original disease, and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> dependence </plain></SENT>
<SENT sid="10" pm="."><plain>Early transplantation, also from alternative donors, may be warranted in patients with poor WBC response to G-CSF </plain></SENT>
<SENT sid="11" pm="."><plain>(Blood </plain></SENT>
<SENT sid="12" pm="."><plain>2000;95:1931-1934) </plain></SENT>
</text></document>